Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Gonadorelin Acetate

FDA-approved product (injectable, injection), marketed as Lutrepulse Kit, Factrel.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Gonadorelin Acetate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Gonadorelin Acetate. Its therapeutic class is shown instead.

WHO therapeutic group
Gonadotropin-releasing hormones; Tests for fertility disturbances
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA63.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli59.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae37.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Gonadorelin Acetate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Gonadorelin Acetate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

    NCT01746849 · start 2012-12

    Registered record
    Registry ID
    NCT01746849
    Conditions
    Leukemia; Multiple Myeloma; Myelodysplastic Syndrome; Non-Hodgkin's Lymphoma
    Interventions
    Palifermin; Lupron; peripheral blood stem cell transplantation; Total-Body Irradiation (TBI); Thiotepa; Cyclophosphamide; Degarelix
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2012-12
    Completion
    2026-12
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Multiple Myeloma; Myelodysplastic Syndrome; Non-Hodgkin's Lymphoma
    InterventionPalifermin; Lupron; peripheral blood stem cell transplantation; Total-Body Irradiation (TBI) +3 more
    PhasePhase 2
    Registry statusActive not recruiting

  • Degarelix in the Treatment of Endometriosis Recurrence

    NCT01712763 · start 2012-11

    Registered record
    Registry ID
    NCT01712763
    Conditions
    Endometriosis
    Interventions
    degarelix; Leuprolide Acetate 11.25 MG/ML (Enantone 11,25)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-11
    Completion
    2016-03
    Enrolment
    360

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis
    Interventiondegarelix; Leuprolide Acetate 11.25 MG/ML (Enantone 11,25)
    PhasePhase 3
    Registry statusCompleted

  • Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer

    NCT01368263 · start 2011-09

    Registered record
    Registry ID
    NCT01368263
    Conditions
    Estrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
    Interventions
    goserelin acetate; letrozole; anastrozole; chemotherapy; Surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2011-09
    Completion
    2013-05
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEstrogen Receptor-positive Breast Cancer; HER2-negative Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer +2 more
    Interventiongoserelin acetate; letrozole; anastrozole; chemotherapy +1 more
    PhasePhase 2
    Registry statusTerminated

  • The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty

    NCT01634321 · start 2011-07

    Registered record
    Registry ID
    NCT01634321
    Conditions
    Central Precocious Puberty
    Interventions
    Luphere depot 3.75mg(Leuprolide acetate 3.75mg)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-07
    Completion
    2012-08
    Enrolment
    63

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCentral Precocious Puberty
    InterventionLuphere depot 3.75mg(Leuprolide acetate 3.75mg)
    PhasePhase 4
    Registry statusCompleted

  • Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer

    NCT01326312 · start 2011-06

    Registered record
    Registry ID
    NCT01326312
    Conditions
    Prostate Cancer
    Interventions
    GTx-758 1000mg; Lupron Depot; GTx-758 2000mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2011-06
    Completion
    2012-12
    Enrolment
    159

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionGTx-758 1000mg; Lupron Depot; GTx-758 2000mg
    PhasePhase 2
    Registry statusTerminated

  • Comparison Between Natural and Artificial Cycle in Recipient Oocyte Patients

    NCT01353846 · start 2011-05

    Registered record
    Registry ID
    NCT01353846
    Conditions
    Infertility
    Interventions
    observation natural cycle; Agonist GnRH; estradiol Valerate; progesterone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2011-05
    Completion
    2012-11
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility
    Interventionobservation natural cycle; Agonist GnRH; estradiol Valerate; progesterone
    PhasePhase 4
    Registry statusUnknown

  • Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration

    NCT01161563 · start 2010-07

    Registered record
    Registry ID
    NCT01161563
    Conditions
    Prostate Cancer
    Interventions
    Triptorelin pamoate; Leuprolide acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-07
    Completion
    2011-04
    Enrolment
    118

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionTriptorelin pamoate; Leuprolide acetate
    PhasePhase 4
    Registry statusCompleted

  • Influence of Male Hormones on Regional Fat Metabolism

    NCT01160328 · start 2010-06

    Registered record
    Registry ID
    NCT01160328
    Conditions
    Obesity
    Interventions
    Leuprolide; Testosterone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-06
    Completion
    2013-01
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObesity
    InterventionLeuprolide; Testosterone
    PhasePhase 1
    Registry statusCompleted

  • A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer

    NCT00924469 · start 2009-11

    Registered record
    Registry ID
    NCT00924469
    Conditions
    Prostate Cancer
    Interventions
    Abiraterone; Leuprolide; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-11
    Completion
    2012-03
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionAbiraterone; Leuprolide; Prednisone
    PhasePhase 2
    Registry statusCompleted

  • Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer

    NCT00860158 · start 2009-03

    Registered record
    Registry ID
    NCT00860158
    Conditions
    Prostate Cancer
    Interventions
    Dasatinib; Leuprolide Acetate (LHRH Analogue); Radical Prostatectomy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2009-03
    Completion
    2010-12
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionDasatinib; Leuprolide Acetate (LHRH Analogue); Radical Prostatectomy
    PhasePhase 2
    Registry statusTerminated

  • Oral Microdose Lupron Versus Luteal Estradiol Trial in Poor Responder In Vitro Fertilization (IVF) Patients

    NCT00826839 · start 2009-01

    Registered record
    Registry ID
    NCT00826839
    Conditions
    Infertility
    Interventions
    Oral contraceptive pill and microdose lupron; E2 patch/antagonist
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2009-01
    Completion
    2012-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfertility
    InterventionOral contraceptive pill and microdose lupron; E2 patch/antagonist
    PhasePhase 4
    Registry statusWithdrawn

  • Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer

    NCT00589472 · start 2007-11

    Registered record
    Registry ID
    NCT00589472
    Conditions
    Prostate Adenocarcinoma; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer
    Interventions
    Bicalutamide; Goserelin Acetate; Laboratory Biomarker Analysis; Leuprolide Acetate; Therapeutic Conventional Surgery; Vorinostat
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-11
    Completion
    2010-06
    Enrolment
    19

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Adenocarcinoma; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer +1 more
    InterventionBicalutamide; Goserelin Acetate; Laboratory Biomarker Analysis; Leuprolide Acetate +2 more
    PhasePhase 2
    Registry statusCompleted

  • Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women

    NCT00322348 · start 2006-04

    Registered record
    Registry ID
    NCT00322348
    Conditions
    Advanced Breast Cancer
    Interventions
    Goserelin acetate; Goserelin acetate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-04
    Completion
    2009-11
    Enrolment
    98

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Breast Cancer
    InterventionGoserelin acetate; Goserelin acetate
    PhasePhase 2
    Registry statusCompleted

  • Treatment of Endometriosis With Norethindrone Acetate ( NA) VS. Gonadotropin- Releasing Hormone (GnRH) Agonist (Lupron Depot 11.25 mg)

    NCT00458458 · start 2004-08

    Registered record
    Registry ID
    NCT00458458
    Conditions
    Endometriosis; Dysmenorrhea; Dyspareunia
    Interventions
    Norethindrone Acetate (NA); GnRH Agonist (Lupron Depot)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2004-08
    Completion
    Not recorded
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis; Dysmenorrhea; Dyspareunia
    InterventionNorethindrone Acetate (NA); GnRH Agonist (Lupron Depot)
    PhasePhase 3
    Registry statusUnknown

  • Clinical Trial for Prostate Cancer

    NCT00076531 · start 2003-12

    Registered record
    Registry ID
    NCT00076531
    Conditions
    Prostate Cancer
    Interventions
    Leuprolide Acetate for Injectable Suspension 22.5 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-12
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionLeuprolide Acetate for Injectable Suspension 22.5 mg
    PhasePhase 3
    Registry statusCompleted